Science
Mechanism of Action
Ilomastat, also known as GM6001 or Galardin, functions as a reversible metallopeptidase inhibitor belonging to the hydroxamic acid class. It exerts its effect by forming a bidentate complex with the active-site zinc atom of various MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-12, MMP-14, and MMP-26. By inhibiting these enzymes, which are responsible for the degradation of essential extracellular matrix components like collagen and elastin, Ilomastat theoretically holds potential for preserving skin structure and mitigating signs of aging.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
Ilomastat is not a commonly used cosmetic ingredient. Its primary applications are as a research chemical and an investigational drug, largely due to its safety profile as a first-generation MMP inhibitor and lack of specific cosmetic efficacy data.
The Formula
Formulation
Stability
Ilomastat itself is insoluble in water but readily dissolves in organic solvents such as DMSO and ethanol. Its aqueous solubility can be significantly enhanced through complexation with cyclodextrins, specifically 2-hydroxypropyl-β-cyclodextrin (Ilomastat-CD), achieving solubilities up to ~1000 μg/mL in water and 1400 μg/mL in PBS (pH 7.4). For research purposes, it has been formulated as suspensions using Tween-80, PEG4000, and ethanol, or as clear solutions with DMSO, PEG300, Tween-80, and saline. Solutions are generally recommended for immediate use to ensure optimal results. A collagenase assay utilizing Ilomastat is typically performed at pH 6.5, but this is not an indicator for optimal cosmetic formulation pH.
Conflicts
- Water (without appropriate solubilizers or complexing agents)
- Potential for the release of toxic hydroxylamine during metabolic processes, due to its hydroxamic acid structure.
Safety
Safety Profile
Comprehensive cosmetic safety assessments by bodies like CIR, SCCS, or FDA are unavailable for Ilomastat. While human clinical trials for ophthalmic applications have been conducted without reported toxicities and in vitro tests showed no obvious cytotoxicity up to 100 µM, a significant concern exists regarding first-generation hydroxamic acid-based MMP inhibitors like Ilomastat. These compounds are known for limited specificity and the potential to release toxic hydroxylamine during human metabolic reactions. Ilomastat's maximum clinical trial phase is II, indicating some human testing but not specifically for cosmetic purposes. The observed delay in human wound healing at 1% topical application also raises concerns about its interaction with skin repair processes.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Given the significant safety concerns related to potential toxic hydroxylamine release and limited specificity, alongside a lack of proven topical skincare efficacy and a reported delay in wound healing at 1% concentration, Ilomastat is not suitable for cosmetic formulations.
Related
Similar Ingredients
Finding similar ingredients…